search
Back to results

Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults

Primary Purpose

Acute Exacerbation of Bronchiectasis

Status
Active
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
anti-infective therapy sitafloxacin
anti-infective therapy levofloxacin
Sponsored by
Shanghai Pulmonary Hospital, Shanghai, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Exacerbation of Bronchiectasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients who older than 18 years old and are diagnosed with acute exacerbations of bronchiectasis Acute exacerbation of bronchiectasis refers to changes in three or more ofthe following six symptoms in patients, including cough frequency, increased sputum volume or nature change, increased purulent sputum with or without wheezing, dyspnea, hemoptysis, and (or) general malaise, lasting for 48 hours or more, and clinicians consider that it is necessary to change the current therapeutic regimen for the condition; It should also be noted that left and right cardiac insufficiency, arrhythmia, pleural effusion, pulmonary embolism, pneumothorax and pneumonia should be noted.
  2. Patients who have not accepted antibacterial drug therapy within 48 hours before initiation of administration or who have accepted other antibacterial drug therapy within 48 hours before initiation of administration but not more than 24 hours (excluding use of quinolones), and still present with apparent symptoms of infection

Exclusion Criteria:

Patients complying with any of the following exclusion criteria cannot be enrolled into this trail:

  1. Bronchiectaticpatientswith previous sputum examinations suggesting the presence of bronchiectasis of pathogenic

    - Page 3 of 5 - microorganisms resistant to quinolone drugscomplicated with chronic respiratory failure

  2. Patients with a previous stable phase BSI score greater than 9
  3. Inhaled, oral or intravenous quinolone antibiotics have been used within 1 week before enrollment.
  4. Patients who have a history of allergy to any quinolone or fluoroquinolone
  5. Patients who have a medical history of pathological changes in the muscle tendon caused by quinolones or fluoroquinolones;
  6. Complicatingbronchial asthma, allergic bronchopulmonary aspergillosis, or active tuberculosis, or active non-tuberculous mycobacterial infection that requires standardized treatment;
  7. A history of complicating serious cardiovascular diseases, hematopoietic system diseases, etc. (such as: congestive heart failure, clinically significant coronary heart disease, stroke, myocardial infarction and/or stroke that occurred within half a year, clinically significant arrhythmia, known aortic aneurysm, poorly controlled hypertension (systolic blood pressure> 160mmHg, or diastolic blood pressure> 100mmHg, etc.in two or more consecutive detections);
  8. Moderate hemoptysis (>30ml in 24h);
  9. Complicatingserious systemic diseases and mental disorders;
  10. Complicatingdiabetic patients with poor control or fasting blood glucose> 10mmol/L;
  11. Complicatingmalignant tumor;
  12. Complicating myasthenia gravis and Parkinson's disease;
  13. Patients with abnormal liver function test, withAST (GOT) and/or ALT (GPT) higher than 3 times the upper limit of normal, and/or total bilirubin higher than twice the upper limit of normal;
  14. Patients with moderate or severe renal hypofunction, withendogenous creatinine clearance rate <50 ml/min (if the examination is not performed, the clearance rate may be calculated from the serum creatinine value using a formula)*;
  15. *Cockcroft-Gault Formula i. Male:eCcr(ml/min)=[(140 - age)

    ×weight(kg)]/[72 ×serum creatinine(mg/dl)] ii. Female:eCcr(ml/ min)=[(140 - age) ×weight(kg) × 0.85]/[72 ×serum creatinine(mg/ dl)] or, iii. Male: eCcr(ml/min)= [(140 - age)×weight(kg)×1.23]/serum creatinine(µmol/l) iv. Male:eCcr(ml/min)= [(140 - age)×weight× 1.04]/serum creatinine(µmol/l)

  16. Patients with a medical history of prolonged QTc interval,or requiring use of drugs to treat prolonged QTc interval (e.g., Class I or III anti-arrhythmic, as detailed in Appendix 1), or suffering serious cardiac insufficiency (NYHA Functional Class ≥ III, as detailed in Appendix 2);
  17. Patients with a medical history of epileptic seizures, or mental disease that may influence the compliance withthe protocol, or with suicide risk, or a history of alcohol or illicit drug abuse;
  18. Immunocompromised patients usingglucocorticoids (with the total dose equivalent to prednisone daily or acourse of treatment of more than 2 weeks) or immunosuppressants, etc.;
  19. Pregnant or lactating women or women of childbearing age who are preparing to conceive;
  20. Those who have participatedin other clinical trials within 3 months prior to screening.

Sites / Locations

  • Shanghai pulmonary hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

sitafloxacin group

levofloxacin group

Arm Description

Oral sitafloxacin (0.1g one time daily) for 10 days

Oral levofloxacin (0.4g one time daily) for 10 days

Outcomes

Primary Outcome Measures

Clinical effectiveness
The clinical effective rate was the percentage of improved cases in the analysis set cases.

Secondary Outcome Measures

microbiological discontinuation of Administration
The effective rate of microbiology is the percentage of cases of clearance, hypothetical clearance, replacement and reinfection in the number of evaluable cases in the analysis set.

Full Information

First Posted
November 12, 2021
Last Updated
April 5, 2022
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
search

1. Study Identification

Unique Protocol Identification Number
NCT05313750
Brief Title
Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults
Official Title
Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults :A Multi-center, Randomized, Evaluator-blinded, Levofloxacin Parallel-controlled Clinical Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 30, 2021 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Pulmonary Hospital, Shanghai, China

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The treatment of acute exacerbation of bronchiectasis requires comprehensive treatment, and antibacterial drug therapy is the key. The study is a multicenter, randomized, evaluator-blinded, levofloxacin parallel-controlled clinical study designed to evaluate the efficacy and safety of sitafloxacin in the treatment of acute exacerbations of bronchiectasis in adults.
Detailed Description
Acute exacerbation of bronchiectasis refers to changes in three or more ofthe following six symptoms in patients with bronchiectasis, including cough frequency, increased sputum volume or nature change, increased purulent sputum with or without wheezing, dyspnea, hemoptysis, and (or) general malaise, lasting for 48 hours or more, and clinicians consider that it is necessary to change the current therapeutic regimen for the condition. The treatment of acute exacerbation of bronchiectasis requires comprehensive treatment, and antibacterial drug therapy is the key. Sitafloxacin has a broad antibacterial spectrum. It has good in vivo and in vitro activities against gram-positive bacteria, gram-negative bacteria, anaerobic bacteria and atypical pathogens and it has excellent pharmacokinetic properties, rapid oral absorption, strong tissue permeability and no liver retention, and no inhibition to main liver drug enzymes of human and it shows good activity against many fluoroquinolone-resistant bacteria. The study aims to evaluate efficacy and safety of sitafloxacin in the treatment of acute exacerbations of bronchiectasis in adults.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Exacerbation of Bronchiectasis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
256 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
sitafloxacin group
Arm Type
Experimental
Arm Description
Oral sitafloxacin (0.1g one time daily) for 10 days
Arm Title
levofloxacin group
Arm Type
Active Comparator
Arm Description
Oral levofloxacin (0.4g one time daily) for 10 days
Intervention Type
Drug
Intervention Name(s)
anti-infective therapy sitafloxacin
Intervention Description
anti-infective therapy
Intervention Type
Drug
Intervention Name(s)
anti-infective therapy levofloxacin
Intervention Description
anti-infective therapy
Primary Outcome Measure Information:
Title
Clinical effectiveness
Description
The clinical effective rate was the percentage of improved cases in the analysis set cases.
Time Frame
24days
Secondary Outcome Measure Information:
Title
microbiological discontinuation of Administration
Description
The effective rate of microbiology is the percentage of cases of clearance, hypothetical clearance, replacement and reinfection in the number of evaluable cases in the analysis set.
Time Frame
10days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who older than 18 years old and are diagnosed with acute exacerbations of bronchiectasis Acute exacerbation of bronchiectasis refers to changes in three or more ofthe following six symptoms in patients, including cough frequency, increased sputum volume or nature change, increased purulent sputum with or without wheezing, dyspnea, hemoptysis, and (or) general malaise, lasting for 48 hours or more, and clinicians consider that it is necessary to change the current therapeutic regimen for the condition; It should also be noted that left and right cardiac insufficiency, arrhythmia, pleural effusion, pulmonary embolism, pneumothorax and pneumonia should be noted. Patients who have not accepted antibacterial drug therapy within 48 hours before initiation of administration or who have accepted other antibacterial drug therapy within 48 hours before initiation of administration but not more than 24 hours (excluding use of quinolones), and still present with apparent symptoms of infection Exclusion Criteria: Patients complying with any of the following exclusion criteria cannot be enrolled into this trail: Bronchiectaticpatientswith previous sputum examinations suggesting the presence of bronchiectasis of pathogenic - Page 3 of 5 - microorganisms resistant to quinolone drugscomplicated with chronic respiratory failure Patients with a previous stable phase BSI score greater than 9 Inhaled, oral or intravenous quinolone antibiotics have been used within 1 week before enrollment. Patients who have a history of allergy to any quinolone or fluoroquinolone Patients who have a medical history of pathological changes in the muscle tendon caused by quinolones or fluoroquinolones; Complicatingbronchial asthma, allergic bronchopulmonary aspergillosis, or active tuberculosis, or active non-tuberculous mycobacterial infection that requires standardized treatment; A history of complicating serious cardiovascular diseases, hematopoietic system diseases, etc. (such as: congestive heart failure, clinically significant coronary heart disease, stroke, myocardial infarction and/or stroke that occurred within half a year, clinically significant arrhythmia, known aortic aneurysm, poorly controlled hypertension (systolic blood pressure> 160mmHg, or diastolic blood pressure> 100mmHg, etc.in two or more consecutive detections); Moderate hemoptysis (>30ml in 24h); Complicatingserious systemic diseases and mental disorders; Complicatingdiabetic patients with poor control or fasting blood glucose> 10mmol/L; Complicatingmalignant tumor; Complicating myasthenia gravis and Parkinson's disease; Patients with abnormal liver function test, withAST (GOT) and/or ALT (GPT) higher than 3 times the upper limit of normal, and/or total bilirubin higher than twice the upper limit of normal; Patients with moderate or severe renal hypofunction, withendogenous creatinine clearance rate <50 ml/min (if the examination is not performed, the clearance rate may be calculated from the serum creatinine value using a formula)*; *Cockcroft-Gault Formula i. Male:eCcr(ml/min)=[(140 - age) ×weight(kg)]/[72 ×serum creatinine(mg/dl)] ii. Female:eCcr(ml/ min)=[(140 - age) ×weight(kg) × 0.85]/[72 ×serum creatinine(mg/ dl)] or, iii. Male: eCcr(ml/min)= [(140 - age)×weight(kg)×1.23]/serum creatinine(µmol/l) iv. Male:eCcr(ml/min)= [(140 - age)×weight× 1.04]/serum creatinine(µmol/l) Patients with a medical history of prolonged QTc interval,or requiring use of drugs to treat prolonged QTc interval (e.g., Class I or III anti-arrhythmic, as detailed in Appendix 1), or suffering serious cardiac insufficiency (NYHA Functional Class ≥ III, as detailed in Appendix 2); Patients with a medical history of epileptic seizures, or mental disease that may influence the compliance withthe protocol, or with suicide risk, or a history of alcohol or illicit drug abuse; Immunocompromised patients usingglucocorticoids (with the total dose equivalent to prednisone daily or acourse of treatment of more than 2 weeks) or immunosuppressants, etc.; Pregnant or lactating women or women of childbearing age who are preparing to conceive; Those who have participatedin other clinical trials within 3 months prior to screening.
Facility Information:
Facility Name
Shanghai pulmonary hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200433
Country
China

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults

We'll reach out to this number within 24 hrs